Drugmakers Buoyed as Trump Deal Eases Worst Fears on Pricing

Wall Street had long feared US President Donald Trump would follow through with threats to impose aggressive drug-pricing policies, eroding the pharmaceutical industry’s profitability and depressing share prices.

Those fears were largely laid to rest this week after Pfizer Inc. cut a deal with the White House.